| Literature DB >> 26260810 |
Anna S Berghoff1,2, Matthias Preusser1,2.
Abstract
Brain metastases (BM) are an increasing challenge in the management of patients with advanced cancer. Treatment options for BM are limited and mainly focus on the application of local therapies. Systemic therapies including targeted therapies are only poorly investigated, as patients with BM were frequently excluded from clinical trials. Several targeted therapies have shown promising activity in patients with BM. In the present review we discuss existing and emerging targeted therapies for the most frequent BM primary tumor types. We focus on challenges in the conduction of clinical trials on targeted therapies in BM patients such as patient selection, combination with radiotherapy, the obstacles of the blood-brain barrier and the definition of study end points.Entities:
Keywords: ALK translocation; EGFR mutation; anti-HER2 therapy; brain metastases; targeted therapies
Mesh:
Substances:
Year: 2015 PMID: 26260810 DOI: 10.2217/fon.15.127
Source DB: PubMed Journal: Future Oncol ISSN: 1479-6694 Impact factor: 3.404